X4 Pharmaceuticals (XFOR) Projected to Post Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR) is anticipated to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.17) per share and revenue of $1.07 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

X4 Pharmaceuticals Price Performance

Shares of XFOR opened at $0.31 on Monday. The company has a 50 day moving average of $0.46 and a two-hundred day moving average of $0.53. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $1.60. The company has a market cap of $52.41 million, a price-to-earnings ratio of -3.41 and a beta of 0.39.

Insider Activity at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at $489,323.70. This represents a 6.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 in the last three months. 1.62% of the stock is owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE boosted its holdings in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 133,502 shares of the company’s stock after buying an additional 22,485 shares during the quarter. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent reporting period. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.